natgillin/translations-raw huggingface dataset:
In an ex vivo rabbit pharmacology study, isolated hearts were exposed to atazanavir, cobicistat, or atazanavir and cobicistat in combination. 
U ex vivo farmakološkom ispitivanju na kunićima, izolirana su se srca izlagala atazanaviru, kobicistatu ili kombinaciji atazanavira i kobicistata.
If overdose occurs with EVOTAZ, the patient must be monitored for evidence of toxicity. 
U slučaju predoziranja lijekom EVOTAZ, bolesnika se mora nadzirati zbog moguće pojave znakova toksičnosti.
Cobicistat reversibly inhibits MATE1, and concentrations of metformin may be increased when co-administered with EVOTAZ. 
Kobicistat reverzibilno inhibira MATE1, pa koncentracije metformina mogu porasti kod istodobne primjene lijeka EVOTAZ.
Among the 19 patients, 1 developed the emtricitabine-associated resistance substitution M184V with no tenofovir or protease inhibitor associated resistance substitutions. 
Od 19 bolesnika, 1 je razvio supstituciju M184V, povezanu s rezistencijom na emtricitabin bez supstitucija povezanih s rezistencijom na tenofovir ili inhibitore proteaze.
Concentrations of these medicinal products may be increased when co-administered with EVOTAZ resulting in the potential for increased adverse events usually associated with these anticancer medicinal products. 
Istodobna primjena s lijekom EVOTAZ može povisiti koncentracije navedenih lijekova, što može pojačati nuspojave koje se obično povezuju s tim lijekovima za liječenje raka.
Of these 692 patients, 613 (300 atazanavir with cobicistat and 313 atazanavir with ritonavir) and 496 (250 atazanavir with cobicistat and 246 atazanavir with ritonavir) received at least 48 and 144 weeks of treatment, respectively. 
Među ta 692 bolesnika, njih 613 (300 liječenih atazanavirom s kobicistatom i 313 liječenih atazanavirom s ritonavirom) primalo je liječenje tijekom najmanje 48 tjedana, a njih 496 (250 liječenih atazanavirom s kobicistatom i 246 liječenih atazanavirom s ritonavirom) tijekom najmanje 144 tjedna.
The safety and efficacy of atazanavir with cobicistat in HIV-1 infected patients were evaluated in the randomised, double-blind, active-controlled phase 3 study GS-US-216-0114 in HIV-1 infected patients with baseline estimated creatinine clearance above 70 ml/min who were treatment-naïve (n = 692). 
Sigurnost i djelotvornost atazanavira u kombinaciji s kobicistatom u bolesnika s HIV-1 infekcijom ocijenjene su u randomiziranom, dvostruko slijepom, aktivnim lijekom kontroliranom ispitivanju faze 3 (GS-US-216-0114) u prethodno neliječenih bolesnika s HIV-1 infekcijom i procijenjenom početnom vrijednošću klirensa kreatinina iznad 70 ml/min (n = 692).
Limited data are available on the development of resistance to atazanavir boosted with cobicistat. 
Dostupni su ograničeni podaci o razvoju rezistencije na atanazavir pojačan kobicistatom.
Teл. 
LOC.
Both asymptomatic first-degree (23%) and second-degree (1%) atrioventricular block were reported in paediatric patients. 
U pedijatrijskih je bolesnika bio prijavljen i asimptomatski atrioventrikularni blok prvog stupnja (23%) i drugog stupnja (1%).
Drospirenone AUC: ↑ 130% Drospirenone Cmax: ↔ Drospirenone Cmin: Not calculated 
Drospirenon AUC: ↑ 130% Drospirenon Cmax: ↔ Drospirenon Cmin: Nije računato
If signs or symptoms of nephrolithiasis occurs, temporary interruption or discontinuation of treatment may be considered. 
Ako se pojave znakovi ili simptomi nefrolitijaze, može se razmotriti privremen ili trajan prekid liječenja.
Systemic exposure to atazanavir at doses that resulted in maternal toxicity was at least equal to or slightly greater than that observed in humans given 400 mg once daily. 
Sistemska izloženost atazanaviru u dozama koje koje su bile toksične za majku bila je barem jednaka ili nešto veća od one opažene u ljudi koji su primali dozu od 400 mg jedanput na dan.
Low levels of metabolites are observed in urine and faeces and do not contribute to the CYP3A inhibitory activity of cobicistat. 
Male količine metabolita pronađene su u mokraći i fecesu, ali one ne pridonose inhibicijskom djelovanju kobicistata na CYP3A.
The co-administration of EVOTAZ with stavudine is not expected to significantly alter the exposure of stavudine. 
Ne očekuje se da će istodobna primjena lijeka EVOTAZ i stavudina značajno promijeniti izloženost stavudinu.
Rashes are usually mild-to-moderate maculopapular skin eruptions that occur within the first 3 weeks of starting therapy with atazanavir. 
Osipi su obično blage do umjereno teške makulopapularne kožne erupcije koje nastaju unutar prva 3 tjedna nakon početka terapije atazanavirom.
In treatment-naïve HIV-1 infected patients 
Prethodno neliječeni bolesnici s HIV-1 infekcijom
Moderate to severe hepatic impairment. 
Umjereno do teško oštećenje jetrene funkcije.
Co-administration of EVOTAZ and medicinal products that induce CYP3A4 is contraindicated or not recommended (see sections 4.3 and 4.5) because, in addition to decreased plasma concentrations of atazanavir due to induction of CYP3A4, decreased plasma concentrations of cobicistat could result in cobicistat plasma levels that are insufficient to achieve adequate pharmacoenhancement of atazanavir. 
Istodobna primjena lijeka EVOTAZ i lijekova koji induciraju CYP3A4 je kontraindicirana ili se ne preporučuje (vidjeti dijelove 4.3 i 4.5); naime, osim što indukcija CYP3A4 smanjuje plazmatske koncentracije atazanavira, smanjene plazmatske koncentracije kobicistata mogle bi dovesti do razina kobicistata u plazmi koje nisu dostatne za postizanje odgovarajućeg farmakokinetičkog pojačanja atazanavira.
AUC: ↔7% (↓11% ↓3%) Cmax: ↓13% (↓20% ↓6%) Cmin: Not determined 
AUC: ↔7% (↓11% ↓3%) Cmax: ↓13% (↓20% ↓6%) Cmin: nije određen
Animal studies are insufficient with respect to reproductive toxicity (see section 5.3). 
Ispitivanja na životinjama nisu dostatna s obzirom na reproduktivnu toksičnost (vidjeti dio 5.3).
The following statements reflect the pharmacokinetic properties of atazanavir in combination with cobicistat or the individual components of EVOTAZ. 
Sljedeći odlomci opisuju farmakokinetička svojstva atazanavira u kombinaciji s kobicistatom ili farmakokinetička svojstva pojedinačnih sastavnica lijeka EVOTAZ.
Viruses were known to be susceptible to atazanavir, emtricitabine and tenofovir DF at baseline. 
Za viruse je na početku ispitivanja utvrđeno da su osjetljivi na atazanavir, emtricitabin i tenofovir DF.
Co-administration of EVOTAZ and tenofovir alafenamide 25 mg for treatment of HBV infection is not recommended 
Ne preporučuje se istodobna primjena lijeka EVOTAZ s 25 mg tenofoviralafenamida za liječenje HBV infekcije.
If you miss a dose of EVOTAZ by 12 hours or less, take it right away with food and then take your next scheduled dose at the usual time. 
Ako primijetite da ste propustili uzeti dozu lijeka EVOTAZ unutar 12 sati od kada ste je trebali uzeti, uzmite je odmah s hranom, a zatim uzmite sljedeću dozu prema uobičajenom rasporedu.
c Includes subjects who had ≥50 copies/ml in the week 48 or 144 windows, subjects who discontinued early due to lack or loss of efficacy, subjects who discontinued for reasons other than an adverse event, death or lack or loss of efficacy and at the time of discontinuation had a viral value of ≥50 copies/ml. 
bOkvir 144. tjedna obuhvaća razdoblje između 967. i 1050. dana (uključujući i te dane) c Uključuje ispitanike koji su imali ≥50 kopija/ml u okviru 48. ili 144. tjedna, ispitanike koji su rano prekinuli liječenje zbog nedostatka ili gubitka djelotvornosti, ispitanike koji su prekinuli liječenje zbog razloga koji nisu bili nuspojava, smrt ili nedostatak ili gubitak djelotvornosti i koji su u trenutku prekida liječenja imali virusnu vrijednost ≥50 kopija/ml.
Co-administration of EVOTAZ with warfarin has the potential to produce serious and/or life-threatening bleeding due to increased warfarin plasma concentrations, and it is recommended that the INR (International Normalized Ratio) be monitored (see section 4.5). 
Istodobna primjena lijeka EVOTAZ s varfarinom može uzrokovati ozbiljno i/ili po život opasno krvarenje zbog povišenih plazmatskih koncentracija varfarina i stoga se preporučuje kontrolirati INR (internacionalni normalizirani omjer) (vidjeti dio 4.5).
Buprenorphine/naloxone in combination with cobicistat 
Buprenorfin/nalokson u kombinaciji s kobicistatom
Two percent of patients treated with atazanavir experienced concurrent Grade 3-4 ALT/AST and Grade 3-4 total bilirubin elevations. 
Dva posto bolesnika liječenih atazanavirom istodobno je imalo povišenje razine ALT-a/AST-a 3.-4. stupnja i povišenje razine ukupnog bilirubina 3.-4. stupnja.
Plasma concentrations of these medicinal products may be increased when co-administered with EVOTAZ, resulting in reduced serum cortisol concentrations. 
Mogu biti povećane koncentracije tih lijekova u plazmi kada se primjenjuju istodobno s EVOTAZOM, što dovodi do smanjenih koncentracija kortizola u serumu.
Exposure to clarithromycin is expected to increase if co-administered with EVOTAZ. 
Očekuje se povećana izloženost klaritromicinu pri istodobnoj primjeni s lijekom EVOTAZ.
This effect may be due to an induction of CYP3A4. 
Taj bi učinak mogao biti posljedica indukcije CYP3A4.
Co-administration with antiretroviral medicinal products EVOTAZ is indicated for use with other antiretrovirals for the treatment of HIV-1 infection. 
EVOTAZ je indiciran u kombinaciji s drugim antiretroviroticima za liječenje HIV-1 infekcije.
However, patients should be informed that dizziness has been reported during treatment with regimens containing atazanavir or cobicistat (see section 4.8). 
Međutim, bolesnike treba upozoriti da je tijekom liječenja režimima koji su sadržavali atazanavir ili kobicistat prijavljena omaglica (vidjeti dio 4.8)
The resistance profile of EVOTAZ is driven by atazanavir. 
Profil rezistencije lijeka EVOTAZ temelji se na atazanaviru.
In the pre- and postnatal development assessment in rats, atazanavir produced a transient reduction in body weight in the offspring at a maternally toxic dose. 
Procjena prenatalnog i postnatalnog razvoja u štakora pokazala je da je atazanavir izazvao prolazno smanjenje tjelesne težine potomstva pri dozama koje su bile toksične za majku.
In HIV-infected patients with severe immune deficiency at the time of institution of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms. 
U bolesnika zaraženih HIV-om koji u trenutku uvođenja kombinirane antiretrovirusne terapije (CART) imaju tešku imunodeficijenciju, može doći do upalne reakcije na asimptomatske ili rezidualne oportunističke patogene, što može prouzročiti ozbiljna klinička stanja ili pogoršanje simptoma.
Effect of cobicistat on atazanavir pharmacokinetics 
Učinak kobicistata na farmakokinetiku atazanavira
In a 3-month combination oral toxicity study of atazanavir and cobicistat in rats, there were no toxicologic interactions apparent as no additive or synergistic toxicities were observed. 
U 3-mjesečnom ispitivanju toksičnosti peroralne primjene kombinacije atazanavira i kobicistata provedenom na štakorima nisu opažene aditivne ni sinergističke toksičnosti te nije bilo primjetnih toksikoloških interakcija.
The mean (± SD) change in estimated glomerular filtration rate (eGFR) by Cockcroft-Gault method after 144 weeks of treatment was -15.1 ± 16.5 ml/min in the atazanavir boosted with cobicistat plus emtricitabine and tenofovir DF fixed-dose combination group and -8.0 ± 16.8 ml/min in the atazanavir boosted with ritonavir plus emtricitabine and tenofovir DF fixed-dose combination group. 
Srednja vrijednost (± SD) promjene procijenjene brzine glomerularne filtracije (engl. estimated glomerular filtration rate, eGFR) izračunate Cockcroft-Gaultovom metodom nakon 144 tjedana liječenja iznosila je -15,1 ± 16,5 ml/min u skupini koja je primala atazanavir pojačan kobicistatom plus kombinaciju fiksne doze emtricitabina i tenofovira DF te -8,0 ± 16,8 ml/min u skupini koja je primala atazanavir pojačan ritonavirom plus kombinaciju fiksne doze emtricitabina i tenofovira DF.
Co-administration of nevirapine and EVOTAZ is expected to increase nevirapine plasma concentrations which may increase the risk of nevirapine-associated toxicity (see section 4.4). 
Očekuje se da će istodobna primjena nevirapina i lijeka EVOTAZ povisiti plazmatske koncentracije nevirapina, što bi moglo povećati rizik od toksičnosti povezane s primjenom nevirapina (vidjeti dio 4.4).
A study of the pharmacokinetics of cobicistat was performed in non-HIV-1 infected subjects with severe renal impairment (estimated creatinine clearance below 30 ml/min). 
Ispitivanje farmakokinetike kobicistata provedeno je u ispitanika bez HIV-1 infekcije koji su imali teško oštećenje funkcije bubrega (procijenjeni klirens kreatinina ispod 30 ml/min).
If this is noticed later than 12 hours of the time it is usually taken, the missed dose should not be taken and the patient should resume the usual dosing schedule. 
Ako primijeti da je propustio uzeti dozu više od 12 sati nakon što ju je trebao uzeti, bolesnik ne treba uzeti propuštenu dozu i treba nastaviti s primjenom prema uobičajenom rasporedu.
Digoxin (0.5 mg single dose)/cobicistat (150 mg multiple doses) 
Digoksin (0,5 mg jednokratna doza)/kobicistat (150 mg, višekratne doze)
Systemic exposures of atazanavir in mice (males), rats, and dogs at doses associated with hepatic changes were at least equal to that observed in humans given 400 mg once daily. 
Sistemska izloženost miševa (mužjaka), štakora i pasa atazanaviru primijenjenom u dozama koje su se povezivale s jetrenim promjenama bila je barem jednaka onoj opaženoj u ljudi koji su primali dozu od 400 mg jedanput na dan.
Nervous system disorders common headache, dizziness, somnolence, dysgeusia uncommon peripheral neuropathy, syncope, amnesia 
Poremećaji živčanog sustava često glavobolja, omaglica, somnolencija, disgeuzija manje često periferna neuropatija, sinkopa, amnezija
Sildenafil, tadalafil, and vardenafil are metabolised by CYP3A4. 
Sildenafil, tadalafil i vardenafil metaboliziraju se putem CYP3A4.
Rosuvastatin AUC: ↑ 242% Rosuvastatin Cmax: ↑ 958% Rosuvastatin Cmin: Not calculated 
Rosuvastatin AUC: ↑ 242% Rosuvastatin Cmax: ↑ 958% Rosuvastatin Cmin: Nije računato
Metabolism and nutrition disorders common increased appetite uncommon weight decreased, weight gain, anorexia 
Poremećaji metabolizma i prehrane često pojačan tek manje često smanjenje tjelesne težine, povećanje tjelesne težine, anoreksija
Rashes are usually mild-to-moderate maculopapular skin eruptions that occur within the first 3 weeks of starting therapy with atazanavir, a component of EVOTAZ. 
Osipi su obično blage do umjerene makulopapularne kožne erupcije koje se javljaju tijekom prva 3 tjedna od početka terapije atazanavirom, sastavnicom lijeka EVOTAZ.
Alternative corticosteroids which are less dependent on CYP3A metabolism, e.g. beclomethasone for intranasal or inhalational use, should be considered, particularly for long term use. 
Potrebno je uzeti u obzir zamjenske kortikosteroide koji manje ovise o metabolizmu putem CYP3A, npr. beklometazon za intranazalnu ili inhalacijsku primjeni, osobito za dugoročnu primjenu.
If you miss a dose and it is more than 12 hours from the time you should have taken EVOTAZ, do not take the missed dose. 
Ako je od propuštanja doze lijeka EVOTAZ prošlo više od 12 sati, nemojte uzeti propuštenu dozu.
If EVOTAZ is missed within 12 hours of the time it is usually taken, patients should be instructed to take the prescribed dose of EVOTAZ with food as soon as possible. 
Ako bolesnik propusti dozu lijeka EVOTAZ i sjeti se unutar 12 sati nakon što ju je trebao uzeti, treba ga uputiti da uzme propisanu dozu lijeka EVOTAZ s hranom što je prije moguće.
Co-administration with EVOTAZ has the potential to produce serious and/or life-threatening bleeding due to increased exposure to warfarin and has not been studied. 
Istodobna primjena s lijekom EVOTAZ može uzrokovati ozbiljno i/ili po život opasno krvarenje zbog povećane izloženosti varfarinu pa nije ispitivana.
EVOTAZ should not be used in combination with products containing the same active components including atazanavir, cobicistat or with fixed-dose products that contain cobicistat. 
EVOTAZ se ne smije primjenjivati u kombinaciji s lijekovima koji sadrže iste djelatne tvari, uključujući atazanavir, kobicistat te lijekove s fiksnom kombinacijom doza koji sadrže kobicistat.
Concomitant use of EVOTAZ and fluticasone or other glucocorticoids that are metabolized by CYP3A4 is not recommended unless the potential benefit of treatment outweighs the risk of systemic corticosteroid effects, including Cushing's syndrome and adrenal suppression (see section 4.5). 
Ne preporučuje se istodobna primjena lijeka EVOTAZ i flutikazona ili drugih glukokortikoida koji se metaboliziraju putem CYP3A4, osim u slučajevima kada moguća korist od liječenja nadmašuje rizik od sistemskih učinaka kortikosteroida, uključujući Cushingov sindrom i supresiju nadbubrežne žlijezde (vidjeti dio 4.5).
Glecaprevir AUC : ↑553% Glecaprevir Cmax : ↑306% (↑215% Glecaprevir Cmin : ↑1330% (↑885% Pibrentasvir AUC : ↑64% (↑48% Pibrentasvir Cmax : ↑29% (↑15% Pibrentasvir Cmin: ↑129% (↑95% Atazanavir AUC : ↑11% (↑3% Atazanavir Cmax : ↔ 0% (↓ Atazanavir Cmin: ↑16% (↑7% * Effect of atazanavir and ritonavir on the first dose of glecaprevir and pibrentasvir is reported. 
Glekaprevir AUC: ↑553% (↑424% Glekaprevir Cmax: ↑306% (↑215% Glekaprevir Cmin: ↑1330% (↑885% Pibrentasvir AUC: ↑64% (↑48% Pibrentasvir Cmax: ↑29% (↑15% ↑45%) Pibrentasvir Cmin: ↑129% (↑95% Atazanavir AUC: ↑11% (↑3% ↑19%) Atazanavir Cmax: ↔ 0% (↓ Atazanavir Cmin: ↑16% (↑7% ↑25%) * Prijavljen je učinak atazanavira i ritonavira na prvu dozu glekaprevira i pibrentasvira.
In clinical study GS-US-216-0114, a phase 3 randomised, active-controlled clinical study, in which 692 treatment-naïve patients received at least one dose of atazanavir boosted with cobicistat (n = 344) or atazanavir boosted with ritonavir (n = 348) administered with other antiretroviral medicinal products, the most frequently reported adverse reactions in the atazanavir boosted with cobicistat group during 144 weeks were associated with elevated bilirubin levels (see Table 2). 
U randomiziranom, aktivnim lijekom kontroliranom kliničkom ispitivanju faze 3 (GS-US-216-0114), u kojem su 692 prethodno neliječena bolesnika primila najmanje jednu dozu atazanavira pojačanog kobicistatom (n = 344) ili atazanavira pojačanog ritonavirom (n = 348) u kombinaciji s drugim antiretrovirusnim lijekovima, najčešće prijavljene nuspojave u skupini liječenoj atazanavirom pojačanim kobicistatom tijekom 144 tjedana bile su povezane s povišenim razinama bilirubina (vidjeti Tablicu 2).
Administration of a single dose of EVOTAZ with a high fat meal (1,038 kcal, 59 g fat, 37 g protein) resulted in a 14% reduction in atazanavir Cmax with no change in atazanavir AUC or cobicistat exposures (Cmax, AUC) relative to the fasting state. 
Primjena jedne doze lijeka EVOTAZ uz obrok s visokim udjelom masnoća (1038 kcal, 59 g masnoća, 37 g proteina) smanjila je Cmax atazanavira za 14%, ali nije utjecala na AUC atazanavira niti na izloženost kobicistatu (Cmax, AUC) u odnosu na primjenu natašte.
In a fertility and early embryonic development study in rats, atazanavir altered oestrus cycling with no effects on mating or fertility. 
U ispitivanju učinaka na plodnost i rani embrionalni razvoj, atazanavir je promijenio estrusni ciklus bez učinaka na parenje ili plodnost.
In a trial where HIV-infected subjects (n=22) were instructed to take atazanavir 300 mg with cobicistat 150 mg once daily with food, the steady-state atazanavir Cmax, AUCtau and Ctau (mean ± SD) values were 3.9 ± 1.9 μg/ml, 46.1 ± 26.2 μg•hr/ml and 0.80 ± 0.72 μg/ml, respectively. 
U ispitivanju u kojem su ispitanici s HIV infekcijom (n=22) uzimali atazanavir u dozi od 300 mg s kobicistatom u dozi od 150 mg jedanput na dan s hranom, vrijednost Cmax, AUCtau i Ctau (srednja vrijednost ± SD) atazanavira u stanju dinamičke ravnoteže iznosila je 3,9 ± 1,9 μg/ml, 46,1 ± 26,2 μg•hr/ml odnosno 0,80 ± 0,72 μg/ml.
Atorvastatin AUC: ↑ 822% Atorvastatin Cmax: ↑ 1785% Atorvastatin Cmin: Not calculated 
Atorvastatin AUC: ↑ 822% Atorvastatin Cmax: ↑ 1785% Atorvastatin Cmin: Nije računato
Indinavir is also associated with indirect (unconjugated) hyperbilirubinaemia due to inhibition of UGT. 
Indinavir se povezuje i s indirektnom (nekonjugiranom) hiperbilirubinemijom uzrokovanom inhibicijom UGT-a.
Co-administration of simvastatin or lovastatin with EVOTAZ is contraindicated due to an increased risk of myopathy including rhabdomyolysis (see section 4.3). 
Istodobna primjena simvastatina ili lovastatina s lijekom EVOTAZ je kontraindicirana zbog povećanog rizika od miopatije, uključujući rabdomiolizu (vidjeti dio 4.3).
Caution is warranted and therapeutic concentration monitoring of these medicinal products is recommended if they are used concomitantly with EVOTAZ. 
Potreban je oprez te se preporučuje kontrolirati terapijske koncentracije navedenih lijekova pri njihovoj istodobnoj primjeni s lijekom EVOTAZ.
Concomitant administration of EVOTAZ with ticagrelor is contraindicated. 
Istodobna primjena lijeka EVOTAZ i tikagrelora je kontraindicirana.
As EVOTAZ contains atazanavir and cobicistat, the adverse reactions associated with each of the individual components may be expected. 
Budući da EVOTAZ sadrži atazanavir i kobicistat, mogu se očekivati nuspojave koje se povezuju s primjenom svake od tih dviju sastavnica pojedinačno.
In 2 controlled clinical studies for combination therapy with other antiretroviral medicinal products 1,806 adult patients receiving atazanavir 400 mg once daily (1,151 patients, 52 weeks median duration and 152 weeks maximum duration) or atazanavir 300 mg boosted with ritonavir 100 mg once daily (655 patients, 96 weeks median duration and 108 weeks maximum duration), the most frequently reported adverse reactions were nausea, diarrhoea and jaundice. 
U 2 kontrolirana klinička ispitivanja kombinirane terapije s drugim antiretroviroticima, 1806 odraslih bolesnika primalo je atazanavir u dozi od 400 mg jedanput na dan (1151 bolesnik, medijan trajanja 52 tjedna, najdulje trajanje 152 tjedna) ili atazanavir u dozi od 300 mg pojačan ritonavirom u dozi od 100 mg jedanput na dan (655 bolesnika, medijan trajanja 96 tjedana, najdulje trajanje 108 tjedana), najčešće prijavljene nuspojave bile su mučnina, proljev i žutica.
Co- administration of EVOTAZ and ticagrelor may increase concentrations of the anticoagulant. 
Istodobna primjena lijeka EVOTAZ i tikagrelora može povisiti koncentracije antikoagulansa.
Tenofovir alafenamide AUC ↑75% (↑55% ↑98%) Cmax ↑80% (↑48% ↑118%) 
Tenofoviralafenamid AUC ↑75% (↑55% ↑98%) Cmax ↑80% (↑48% ↑118%)
In HIV-infected patients with severe immune deficiency at the time of initiation of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic infections may arise. 
U bolesnika s HIV infekcijom i teškom imunodeficijencijom u trenutku započinjanja kombinirane antiretrovirusne terapije može nastupiti upalna reakcija na asimptomatske ili rezidualne oportunističke infekcije.
Patients should not breast-feed while taking EVOTAZ. 
Bolesnice ne bi smjele dojiti tijekom uzimanja lijeka EVOTAZ.
Do not take EVOTAZ: if you are allergic to atazanavir, cobicistat or any of the other ingredients of this medicine (listed in section 6) if you have moderate to severe liver problems if you are taking any of these medicines: see also Other medicines and EVOTAZ 
Nemojte uzimati EVOTAZ: ako ste alergični na atazanavir, kobicistat ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.) ako imate umjerene do teške jetrene tegobe ako uzimate neki od ovih lijekova: pogledajte i dio 'Drugi lijekovi i EVOTAZ' rifampicin (antibiotik za liječenje tuberkuloze) karbamazepin, fenobarbital i fenitoin (antiepileptici koji se koriste za sprječavanje napadaja)
The mechanism of interaction is CYP3A inhibition. 
Mehanizam interakcije je inhibicija CYP3A.
How to take EVOTAZ 
Kako uzimati EVOTAZ